Clinical Trials
12 trialsNCT01737502 2025-09-05
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Mayo Clinic
Phase 1/2 Completed
NCT04348292 2024-08-22
Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
Emory University
Phase 1 Terminated
NCT03217669 2023-05-03
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy
University of Kansas Medical Center
Phase 1 Unknown
NCT01383668 2020-04-01
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer
Mayo Clinic
Phase 1 Withdrawn
NCT00923273 2019-11-26
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01390818 2017-03-07
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
EMD Serono
Phase 1 Completed
NCT02126527 2016-08-26
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer
Mayo Clinic
Phase 1 Withdrawn
NCT01155258 2016-06-13
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Phase 1 Completed
NCT00555256 2016-05-06
SU/Rapamycin
Washington University School of Medicine
Phase 1 Completed
NCT00993499 2015-10-07
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (RapamuneĀ®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib
Boehringer Ingelheim
Phase 1 Completed
NCT00079235 2013-07-16
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098462 2012-10-04
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn